Literature DB >> 21165637

Camptocormia phenotype of FSHD: a clinical and MRI study on six patients.

Berit Jordan1, Katharina Eger, Sabrina Koesling, Stephan Zierz.   

Abstract

Recently it has been postulated that there is an atypical facioscapulohumeral muscular dystrophy (FSHD) phenotype with isolated axial myopathy. Involvement of paraspinal and limb muscles was evaluated in six patients with molecularly proven FSHD and a predominant bent spine phenotype. Consistent with the camptocormia phenotype, the most severely affected muscles in all six patients were the thoracic and lumbar spinal tract together with hamstrings. MRI disclosed severe axial muscle degeneration but mostly subclinical involvement of limb muscles. The involvement of hip extensor muscles in FSHD might considerably contribute to the clinical phenotype of camptocormia due to axial muscle involvement.

Entities:  

Mesh:

Year:  2010        PMID: 21165637     DOI: 10.1007/s00415-010-5858-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  46 in total

Review 1.  Molecular diagnosis of facioscapulohumeral muscular dystrophy.

Authors:  Meena Upadhyaya; David N Cooper
Journal:  Expert Rev Mol Diagn       Date:  2002-03       Impact factor: 5.225

2.  Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI.

Authors:  David B Olsen; Peter Gideon; Tina Dysgaard Jeppesen; John Vissing
Journal:  J Neurol       Date:  2006-06-13       Impact factor: 4.849

3.  Studies in disorders of muscle. II Clinical manifestations and inheritance of facioscapulohumeral dystrophy in a large family.

Authors:  F H TYLER; F E STEPHENS
Journal:  Ann Intern Med       Date:  1950-04       Impact factor: 25.391

4.  Beevor's sign in facioscapulohumeral muscular dystrophy: an old sign with new implications.

Authors:  Katharina Eger; Berit Jordan; Sylvia Habermann; Stephan Zierz
Journal:  J Neurol       Date:  2009-10-17       Impact factor: 4.849

5.  FSH dystrophy 4q35 deletion in patients presenting with facial-sparing scapular myopathy.

Authors:  K J Felice; W A North; S A Moore; K D Mathews
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

6.  Axial myopathy due to primary amyloidosis.

Authors:  Yael Friedman; John T Paul; Jean Turley; Lili-Naz Hazrati; David Munoz
Journal:  Muscle Nerve       Date:  2007-10       Impact factor: 3.217

7.  Fat content of lumbar paraspinal muscles in patients with chronic low back pain and in asymptomatic volunteers: quantification with MR spectroscopy.

Authors:  Bernard Mengiardi; Marius R Schmid; Norbert Boos; Christian W A Pfirrmann; Florian Brunner; Achim Elfering; Juerg Hodler
Journal:  Radiology       Date:  2006-09       Impact factor: 11.105

8.  Axial myopathy--an unrecognised entity.

Authors:  Ibrahim Mahjneh; G Marconi; A Paetau; A Saarinen; T Salmi; H Somer
Journal:  J Neurol       Date:  2002-06       Impact factor: 4.849

9.  Facioscapulohumeral muscular dystrophy presenting isolated monomelic lower limb atrophy. Report of two patients with and without 4q35 rearrangement.

Authors:  A Uncini; G Galluzzi; A Di Muzio; M V De Angelis; E Ricci; C Scoppetta; S Servidei
Journal:  Neuromuscul Disord       Date:  2002-11       Impact factor: 4.296

10.  Late-onset axial myopathy with cores due to a novel heterozygous dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene.

Authors:  Heinz Jungbluth; Suzanne Lillis; Haiyan Zhou; Stephen Abbs; Caroline Sewry; Michael Swash; Francesco Muntoni
Journal:  Neuromuscul Disord       Date:  2009-03-19       Impact factor: 4.296

View more
  18 in total

1.  Camptocormia: don't forget muscle disease in the movement disorder clinic.

Authors:  Karen M Doherty; Laura Silveira-Moriyama; Nir Giladi; Kailash P Bhatia; Matt Parton; Andrew J Lees
Journal:  J Neurol       Date:  2012-02-17       Impact factor: 4.849

2.  [Facioscapulohumeral muscular dystrophy. Clinical picture, atypical forms, diagnostics, genetics].

Authors:  B Jordan; C Müller-Reible; S Zierz
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

Review 3.  Magnetic resonance imaging patterns of muscle involvement in genetic muscle diseases: a systematic review.

Authors:  Doris G Leung
Journal:  J Neurol       Date:  2016-11-25       Impact factor: 4.849

Review 4.  Facioscapulohumeral Muscular Dystrophy.

Authors:  Jeffrey M Statland; Rabi Tawil
Journal:  Continuum (Minneap Minn)       Date:  2016-12

Review 5.  Camptocormia in Parkinson's disease: definition, epidemiology, pathogenesis and treatment modalities.

Authors:  Prachaya Srivanitchapoom; Mark Hallett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-04-20       Impact factor: 10.154

6.  [Causes of camptocormia].

Authors:  F X Glocker; U G Berninger
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

7.  Clinical Muscle Testing Compared with Whole-Body Magnetic Resonance Imaging in Facio-scapulo-humeral Muscular Dystrophy.

Authors:  J U Regula; L Jestaedt; F Jende; A Bartsch; H-M Meinck; M-A Weber
Journal:  Clin Neuroradiol       Date:  2015-04-10       Impact factor: 3.649

8.  Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy.

Authors:  Isabella Scionti; Francesca Greco; Giulia Ricci; Monica Govi; Patricia Arashiro; Liliana Vercelli; Angela Berardinelli; Corrado Angelini; Giovanni Antonini; Michelangelo Cao; Antonio Di Muzio; Maurizio Moggio; Lucia Morandi; Enzo Ricci; Carmelo Rodolico; Lucia Ruggiero; Lucio Santoro; Gabriele Siciliano; Giuliano Tomelleri; Carlo Pietro Trevisan; Giuliana Galluzzi; Woodring Wright; Mayana Zatz; Rossella Tupler
Journal:  Am J Hum Genet       Date:  2012-04-06       Impact factor: 11.025

Review 9.  Facioscapulohumeral muscular dystrophy.

Authors:  Jeffrey Statland; Rabi Tawil
Journal:  Neurol Clin       Date:  2014-05-15       Impact factor: 3.806

Review 10.  Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.

Authors:  Johanna Hamel; Rabi Tawil
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.